RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery
2014-01-01 Lopci, E; Bello, L; Olivari, L; Raneri, F; Simonelli, M; Riva, M; Navarria, P; Zucali, Pa; Colombo, P; Scorsetti, M; Santoro, A; Chiti, A
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF
2013-01-01 Zucali, Pa; Simonelli, M; De Vincenzo, F; Santoro, A; Lambiase, A; Bordignon, C
Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC)
2010-01-01 Zucali, P; Santoro, A; Rodriguez-Lope, C; Simonelli, M; Camacho, Lh; Senzer, Nn; Bolondi, L; Lamar, M; Abbadessa, G; Schwartz, Be
High incidence of hypocalcemia in patients with bone metastases from different kinds of neoplasms, treated with zoledronate
2006-01-01 Zuradelli, M; Masci, G; Tronconi, Mc; Rimassa, L; Gullo, G; Pressiani, T; Simonelli, M; Morenghi, E; Biancofiore, G; Santoro, A
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF
2012-01-01 Zucali, Pa; Simonelli, M; De Vincenzo, F; Lorenzi, E; Santoro, A; Lambiase, A; Bordignon, C
MODULATION OF IL-2 CANCER IMMUNOTHERAPY BY CYCLOOXYGENASE (COX)-2 INHIBITORS: THERAPEUTIC AND BIOLOGICAL RESULTS OF IL-2 PLUS CELECOXIB IN METASTATIC RENAL CELL CANCER (RCC) PROGRESSING ON IL-2 ALONE
2004-01-01 Lissoni, P; Vaghi, M; Frontini, L; Ardizzoia, A; Pressiani, T; Colombo, I; Simonelli, M; Gardani, G
NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)
2011-01-01 De Vincenzo, F; Rossoni, G; Santoro, A; Gregorc, V; Zucali, Pa; Citterio, G; Simonelli, M; Petrella, G; Caligaris-Cappio, F; Lambiase, A; Bordignon, C
Outcome evaluation of patients with diagnosed WHO grade III glioma treated according to the molecular profile, the hystology, and the extent of resection (EOR)
2016-01-01 Navarria, P; Pessina, F; Bello, L; Ascolese, Am; DE ROSE, F; D'Agostino, Gr; Franzese, C; Comito, T; Bizzi, A; Simonelli, M; Santoro, A; Cozzi, L; Tomatis, S; Scorsetti, M
Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028
2015-01-01 Ott, Pa; Piha-Paul, Sa; Munster, P; Pishvaian, Mj; Van Brummelen, E; Cohen, R; Gomez-Roca, C; Ejadi, S; Stein, M; Chan, E; Simonelli, M; Morosky, A; Yuan, Ss; Koshiji, M; Bennouna, J
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S)
2012-01-01 Simonelli, M; Zucali, Pa; Lorenzi, E; Rubino, L; De Vincenzo, F; Perrino, M; Rimassa, L; Giordano, L; Santoro, A
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery | 1-gen-2014 | Lopci, E; Bello, L; Olivari, L; Raneri, F; Simonelli, M; Riva, M; Navarria, P; Zucali, Pa; Colombo, P; Scorsetti, M; Santoro, A; Chiti, A | |
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF | 1-gen-2013 | Zucali, Pa; Simonelli, M; De Vincenzo, F; Santoro, A; Lambiase, A; Bordignon, C | |
Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC) | 1-gen-2010 | Zucali, P; Santoro, A; Rodriguez-Lope, C; Simonelli, M; Camacho, Lh; Senzer, Nn; Bolondi, L; Lamar, M; Abbadessa, G; Schwartz, Be | |
High incidence of hypocalcemia in patients with bone metastases from different kinds of neoplasms, treated with zoledronate | 1-gen-2006 | Zuradelli, M; Masci, G; Tronconi, Mc; Rimassa, L; Gullo, G; Pressiani, T; Simonelli, M; Morenghi, E; Biancofiore, G; Santoro, A | |
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF | 1-gen-2012 | Zucali, Pa; Simonelli, M; De Vincenzo, F; Lorenzi, E; Santoro, A; Lambiase, A; Bordignon, C | |
MODULATION OF IL-2 CANCER IMMUNOTHERAPY BY CYCLOOXYGENASE (COX)-2 INHIBITORS: THERAPEUTIC AND BIOLOGICAL RESULTS OF IL-2 PLUS CELECOXIB IN METASTATIC RENAL CELL CANCER (RCC) PROGRESSING ON IL-2 ALONE | 1-gen-2004 | Lissoni, P; Vaghi, M; Frontini, L; Ardizzoia, A; Pressiani, T; Colombo, I; Simonelli, M; Gardani, G | |
NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM) | 1-gen-2011 | De Vincenzo, F; Rossoni, G; Santoro, A; Gregorc, V; Zucali, Pa; Citterio, G; Simonelli, M; Petrella, G; Caligaris-Cappio, F; Lambiase, A; Bordignon, C | |
Outcome evaluation of patients with diagnosed WHO grade III glioma treated according to the molecular profile, the hystology, and the extent of resection (EOR) | 1-gen-2016 | Navarria, P; Pessina, F; Bello, L; Ascolese, Am; DE ROSE, F; D'Agostino, Gr; Franzese, C; Comito, T; Bizzi, A; Simonelli, M; Santoro, A; Cozzi, L; Tomatis, S; Scorsetti, M | |
Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 | 1-gen-2015 | Ott, Pa; Piha-Paul, Sa; Munster, P; Pishvaian, Mj; Van Brummelen, E; Cohen, R; Gomez-Roca, C; Ejadi, S; Stein, M; Chan, E; Simonelli, M; Morosky, A; Yuan, Ss; Koshiji, M; Bennouna, J | |
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S) | 1-gen-2012 | Simonelli, M; Zucali, Pa; Lorenzi, E; Rubino, L; De Vincenzo, F; Perrino, M; Rimassa, L; Giordano, L; Santoro, A |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 4 Contributo in Atti di Convegno ... 35
- 4 Contributo in Atti di Convegno ... 34
- 4 Contributo in Atti di Convegno ... 1
Data di pubblicazione
- 2010 - 2017 29
- 2004 - 2009 6
Rivista
- JOURNAL OF CLINICAL ONCOLOGY 15
- ANNALS OF ONCOLOGY 9
- EUROPEAN JOURNAL OF CANCER 3
- JOURNAL OF THORACIC ONCOLOGY 2
- NEURO-ONCOLOGY 2
- EUROPEAN ASSOCIATION OF NEUROONCO... 1
- EUROPEAN JOURNAL OF CANCER. SUPPL... 1
- EUROPEAN JOURNAL OF NUCLEAR MEDIC... 1
- INTERNATIONAL JOURNAL OF RADIATIO... 1
Accesso al fulltext
- no fulltext 35